STRYKAGEN CORPORATION
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.0Mattributed |
|---|---|
| Latest round | grant, $2.0M, 2023-09-01attributed |
| Founded | unknown |
| Headquarters | RENO, Nevada, USA |
| Industry | bio |
| Stage | unknown |
| Website | strykagen.com |
StrykaGen develops integrin-targeted therapeutics and companion diagnostics for rare muscle diseases like DMD, BMD, MDC1A, and LGMD. It serves patients with rare muscular dystrophies and the pharma partners that may license its assets. Lab facilities at the University of Nevada School of Medicine support both small-molecule and biologic discovery.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-09-01 | grant | $2.0M | undisclosed |
Detected tech stack
Typekit, Adobe Fonts, Afterpay, Sentry, Spin.js, Squarespace, Squarespace Commerce, Stimulus, parallax.js, web-vitals, moment 0, @sentry/browser
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | strykagen.com, read 2026-05-07 |
| Description | self-reported | strykagen.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.